FGFR2 and neoplasm: These patients present lower overall survival rates, lower progression-free survival, and higher recurrence risks and more frequently have poorly differentiated adenocarcinoma, lymph node metastasis, peritoneal seeding, and distant metastasis, as FGFR2 signaling promotes migration and invasion in gastric cancer cells, as well as promoting an angiogenic tumor microenvironment [23,26,48,49,50,51,52,53,54,55,56,57,58,59].